Novartis says the acquisition of Massachusetts-based biotech firm CoStim will accelerate its cancer immunotherapy programme but will not add any new technology.
Outdated technology is one of the greatest challenges in creating next-generation biodrugs, says Jonathan Robinson, who is leading the development of a £38m ($63m) national biomanufacturing hub in the UK.
Big Pharma takeovers of small biopharmaceutical companies to refill pipelines increased the volume and value of dealmaking in Q4 according to a new report by PwC.
Downstream processing techs are harder to use and the focus of less innovation than systems employed upstream says the team developing the UK's new National Biologics Manufacturing Centre.
Inflectra has been launched in Central and Eastern Europe (CEE) and, as the world’s first monoclonal antibody biosimilar drug goes from strength-to-strength, has also been approved by Health Canada.
Scientists at Caltech have published a study in Nature Medicine this week demonstrating that a gene therapy technique that boosts a mouse’s protection against HIV also works against HIV that’s transmitted via mucosal surfaces.
Cobra says it will no longer need to rely on third-parties for its biologics quality control tests after receiving an extension to its GMP certification at a Swedish facility.
GSK has unveiled designs for the £350m ($587m) biomanufacturing plant it intends to build in UK and confirmed that construction will start early next year.
The US Food and Drug Administration (FDA) has issued Amgen with a Warning Letter at its Thousand Oaks, California plant citing violations in the production of monoclonal antibody combination products.
The new Centre for Cell Manufacturing Ireland (CCMI) in Galway means Ireland-based scientists will be able to manufacture culture-expanded stem cells for drug research for the first time.
Industry group BIO has responded to a petition by the Generic Pharmaceutical Association (GPhA) in the latest bout of the debate over the international non-proprietary name (INN) for biosimilars.
Mylan says it will continue to manufacture and sell its Indian version of trastuzumab despite an injunction by Roche restricting reference to it as a biosimilar of Herceptin.
Ski cheats planning to use human growth hormone (HGH) at the Winter Olympics may want to think twice as WADA expects a test for the biopharmaceutical to be available again soon.
Lab rats are not the only animals to play a role in bologics development as Biopharma-Reporter.com discovered when it donned its wellington boots and took a wonder down to the pharm...
Thermo Fisher Scientific has confirmed that the price cuts imposed by Chinese M&A authorities are part of the country’s efforts to become and biopharmaceutical hub.
AbbVie has invested $320m (€432m) into its first Asian manufacturing facility and says it will support an emerging antibody-drug conjugate (ADC) pipeline.
BioOutsource says it has quadrupled its revenue from biologics testing and biosimilar characterisation in the last 18 months and is opening a new facility to cope with continued demand.
Commercial-scale hES culturing is now a possibility thanks to a new technique that - the developers claim - resolves the ethical, technical and regulatory issues that have held back research.
It is no clearer how the US will govern biosimilar naming, approval and substitution despite a day-long Federal Trade Commission (FTC) workshop that produced heated debate but few concrete answers.
German regulators have approved a 3D manufacturing process that Pluristem Therapeutics claims can produce cell therapies faster and more cheaply than standard methods.
Biologics could be delivered by routes other than injection using nanobodies one tenth the size of an antibody, Ablynx says as it extends its license with Merck & Co.
Thermo Fisher Scientific completed its takeover of Life Technologies last night, just two days after the US Federal Trade Commission (FTC) approved the $13.6bn deal.
Sanofi and French biopharma Transgene will soon begin construction on their new €10m ($13.5m) manufacturing plant, which will produce viral vectors for Transgene's targeted cancer immunotherapy, TG4010.
Shipments of chicken pox vaccines from a troubled Belgian facility should recommence in early Q2 2014, says GSK, though the root cause of the manufacturing issues are still unknown.
Politics might not be the only obstacle in getting biosimilars approved in the US, though much of the rest of the world seems intent on obtaining approvals as fast as possible, according to a new report from research company Frost & Sullivan.
The end of Lonza’s biosimilar joint venture with Teva will not affect manufacturing capacity, the firm says, as it reports a drop in overall revenue for 2013.
PharmaCell, the CMO that makes Provenge for Dendreon in Europe, has agreed to buy a facility from TiGenix to add capacity and a manufacturing contract for a second commercial product.
US defence contractor Nanotherapeutics will use a modular biomanufacturing system provided by GE Healthcare at a facility it is building in Alachua, Florida.
Biosimilars could save the US healthcare budget a quarter of a trillion dollars, says Hospira who expects to submit its first application to the USFDA within a year.
Synthetically engineered tracheas may be marketed sooner than previously thought as a Harvard Bioscience spinoff prepares to produce the “scaffolds” for growing tracheas in more clinical trials.
Biocon has defended criticism of the high price of its Trastuzumab biosimilar which will become the world's first copycat version of Roche’s Herceptin when launched next month.
Royal DSM has confirmed that its biologics manufacturing operations and new Australian facility will be part of the business merged with Patheon in its agreement with JLL.
WuXi PharmaTech has predicted that demand for its biopharmaceutical manufacturing services will increase this year just days after upping its guidance for fiscal 2013.
Buying ATMI will help Pall fill gaps in its up and downstream biomanufacturing tech offerings but the deal does not rule out other acquisitions says CEO, Larry Kingsley
Shire has divested its regenerative skingraft product Dermagraft to Organogenesis citing a loss of financial incentive due to new Medicare ruling regarding reimbursement.
The US regulatory scientists who oversee biopharmaceuticals appear to be getting the funding they asked for after politicians pass a $1.2tr (€882bn) Government spending plan for fiscal 2014.
The evaluation of Genmab’s Duobody platform for the discovery and development of bispecific antibodies strengthens Eli Lilly’s biologics programme, the firm says.
Chinese authorities have given Thermo Fisher Scientific the green light to buy Life Technologies on the condition it discounts certain products sold in the coutry.
